½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting


»¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

021-54845833/15800441009

Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ¿ÆÑп¹Ìå > Ò»¿¹ > СÊó¿¹RARRES1µ¥¿Ë¡¿¹Ìå

²úÆ·ÖÐÐÄ

×îвúÆ·

  • СÊó¿¹RARRES1µ¥¿Ë¡¿¹Ìå

    ¹æ¸ñ£º
    ¼Û¸ñ£º£¤
    • Æ·ÅÆ : ͨεÉúÎï
    • Ŀ¼ºÅ : TW11837
    • Ó¦Óà : ½ö¹©¿ÆÑÐʹÓÃ
    • »õÆÚ : ÏÖ»õ
    • ¹æ¸ñ £º100ul
  • ÉÌÆ·ÏêÇé
  • ²Î¿¼ÎÄÏ×
  • ˵Ã÷ÊéÏÂÔØ
  • ÉÌÆ·ÆÀÂÛ0
  • Ïà¹Ø²úÆ·

ÖÐÎÄÃû³Æ: СÊó¿¹RARRES1µ¥¿Ë¡¿¹Ìå

Ó¢ÎÄÃû³Æ: Anti-RARRES1 mouse monoclonal antibody

±ð    Ãû: LXNL; PERG-1; TIG1

¿¹    Ô­: RARRES1

´¢    ´æ: Àä¶³£¨-20¡æ£© ±Ü¹â

ËÞ    Ö÷: Mouse

·´Ó¦ÖÖÊô: Human

Ïà¹ØÀà±ð: Ò»¿¹

±ê ¼Ç Îï: Unconjugate

¿Ë¡ÀàÐÍ: mouse monoclonal

¼¼Êõ¹æ¸ñ

Background:

This gene was identified as a retinoid acid (RA) receptor-responsive gene. It encodes a type 1 membrane protein. The expression of this gene is upregulated by tazarotene as well as by retinoic acid receptors. The expression of this gene is found to be downregulated in prostate cancer, which is caused by the methylation of its promoter and CpG island. Alternatively spliced transcript variant encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008].

Applications:

WB, IHC, IF

Name of antibody:

RARRES1

Immunogen:

Fusion protein of human RARRES1

Full name:

retinoic acid receptor responder (tazarotene induced) 1 (RARRES1), transcript variant 1

Synonyms:

LXNL; PERG-1; TIG1

SwissProt:

P49788

IHC positive control:

human pancreas tissue and carcinoma of human bladder tissue

IHC Recommend dilution:

30-150

WB Predicted band size:

33 kDa

WB Positive control:

HepG2, Hela, SVT2, A549, COS7, Jurkat, MDCK, MCF-7 cell lysates

WB Recommended dilution:

500-2000



¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿